0.7158 0.00 (0.00%)
Pre-Market: 8:00AM EDT
Previous Close | 0.6850 |
Open | 0.6850 |
Bid | 0.6950 x 900 |
Ask | 0.7700 x 1000 |
Day's Range | 0.6851 - 0.7400 |
52 Week Range | 0.3200 - 1.6300 |
Volume | 461,926 |
Avg. Volume | 3,248,471 |
Market Cap | 32.626M |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0660 |
Earnings Date | Nov 13, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.00 |
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access" released by the National Development and Reform Commission and the Ministry of Commerce in April. This statement follows the release of the Overall Plan for the Construction of Hainan Free Trade Port in June 2020 and the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot District in 2013, which were both approved by the State Council.
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2020.
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2020.